Sana Biotechnology, Inc.: insider trades · United States · SEC (Form 4)

About Sana Biotechnology, Inc.

Sana Biotechnology, Inc. is a United States-based biotechnology company listed on the NASDAQ under the ticker SANA. Headquartered in Seattle, Washington, the company was founded in July 2018 and launched publicly in January 2019. Sana is building an engineered-cell platform intended to create a new class of medicines by combining gene delivery, cell therapy, stem cell biology, immunology, and gene editing. From an investor’s perspective, Sana is best understood as a development-stage, pre-commercial biotech focused on high-unmet-need diseases rather than a diversified commercial healthcare company. The company’s core strategy is centered on “hypoimmune” or HIP technology, which is designed to help transplanted cells evade immune detection and potentially function without chronic immunosuppression. This technology underpins Sana’s work in cell replacement and in vivo and ex vivo engineered medicines. The company’s lead and most visible programs include SC451, a stem cell-derived, HIP-modified therapy for type 1 diabetes; UP421, an islet-cell transplantation program generating human clinical data in type 1 diabetes; and oncology/autoimmune assets such as SC291 and the preclinical SG293 program. Sana has also referenced additional programs in its broader pipeline, including fusogen-based approaches such as SG227. Sana’s competitive position is defined by scientific differentiation rather than commercial scale. In cell and gene therapy, success typically depends on three factors: reproducible manufacturing, clear clinical proof of concept, and a credible regulatory path. Sana’s HIP platform is designed to address one of the field’s biggest bottlenecks: immune rejection. That makes the company potentially differentiated versus conventional autologous or immunosuppression-dependent approaches, but it also means execution risk is high and timelines can be unpredictable. Geographically, Sana operates from Seattle, Cambridge, and South San Francisco, reflecting a multi-site U.S. R&D footprint. The company has also highlighted manufacturing and translational capabilities in the United States, which is important given the complexity of cell therapy production. In recent months, Sana has reported continued positive clinical data from its type 1 diabetes transplant study, including 14-month follow-up results showing survival and function of hypoimmune-modified islet cells without immunosuppression. It also announced a strategic collaboration with Mayo Clinic in 2026, aimed at improving type 1 diabetes care and accelerating SC451 development. Sana said it continues to prepare for a Phase 1 trial for SC451 and for clinical advancement of SG293 in non-Hodgkin lymphoma. For international investors, Sana Biotechnology should be viewed as a high-risk, high-upside U.S. NASDAQ biotechnology name. The investment case is driven by pipeline optionality, platform validation, and clinical data readouts, while the main risks remain financing needs, dilution, regulatory uncertainty, and the possibility that early signals do not translate into durable therapeutic or commercial success.